Cargando…

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy

Detalles Bibliográficos
Autores principales: La, V., Fujikawa, R., Janzen, D. M., Nunez, M., Bainvoll, L., Hwang, L., Faull, K., Lawson, G., Memarzadeh, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355127/
https://www.ncbi.nlm.nih.gov/pubmed/34376794
http://dx.doi.org/10.1038/s41698-021-00217-9
_version_ 1783736708049666048
author La, V.
Fujikawa, R.
Janzen, D. M.
Nunez, M.
Bainvoll, L.
Hwang, L.
Faull, K.
Lawson, G.
Memarzadeh, S.
author_facet La, V.
Fujikawa, R.
Janzen, D. M.
Nunez, M.
Bainvoll, L.
Hwang, L.
Faull, K.
Lawson, G.
Memarzadeh, S.
author_sort La, V.
collection PubMed
description
format Online
Article
Text
id pubmed-8355127
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-83551272021-08-30 Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy La, V. Fujikawa, R. Janzen, D. M. Nunez, M. Bainvoll, L. Hwang, L. Faull, K. Lawson, G. Memarzadeh, S. NPJ Precis Oncol Retraction Note Nature Publishing Group UK 2021-08-09 /pmc/articles/PMC8355127/ /pubmed/34376794 http://dx.doi.org/10.1038/s41698-021-00217-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Retraction Note
La, V.
Fujikawa, R.
Janzen, D. M.
Nunez, M.
Bainvoll, L.
Hwang, L.
Faull, K.
Lawson, G.
Memarzadeh, S.
Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
title Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
title_full Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
title_fullStr Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
title_full_unstemmed Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
title_short Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
title_sort retraction note: birinapant sensitizes platinum-resistant carcinomas with high levels of ciap to carboplatin therapy
topic Retraction Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355127/
https://www.ncbi.nlm.nih.gov/pubmed/34376794
http://dx.doi.org/10.1038/s41698-021-00217-9
work_keys_str_mv AT lav retractionnotebirinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy
AT fujikawar retractionnotebirinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy
AT janzendm retractionnotebirinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy
AT nunezm retractionnotebirinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy
AT bainvolll retractionnotebirinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy
AT hwangl retractionnotebirinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy
AT faullk retractionnotebirinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy
AT lawsong retractionnotebirinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy
AT memarzadehs retractionnotebirinapantsensitizesplatinumresistantcarcinomaswithhighlevelsofciaptocarboplatintherapy